Clinical Trial Update: Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma [Phase 2]

View source ↗

Summary

An ongoing Phase 2 study evaluating maintenance therapy with ruxolitinib after hematopoietic stem cell transplant in patients with T-cell lymphoma and graft-ver…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Graft-versus-host Disease
• Peripheral T-cell Lymphoma
• T-cell Leukemia Lymphoma
• T-cell Lymphoma
• T-cell Prolymphocytic Leukemia

Drugs mentioned

• Ruxolitinib (Jakafi) (ruxolitinib)

Snippet

Sponsor: Jonathan Brammer | Conditions: T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Status: RECRUITING